-
公开(公告)号：US10195188B2
公开(公告)日：2019-02-05
申请号：US15694363
申请日：2017-09-01
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC: A61K31/444 , A61K31/519 , A61K31/513 , A61K31/506 , A61K31/555 , A61K45/06 , A61K31/4745 , A61K31/282 , A61K31/7068 , A61K31/337
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US11285138B2
公开(公告)日：2022-03-29
申请号：US16184535
申请日：2018-11-08
Applicant: CHEMOCENTRYX, INC.
Inventor： Petrus Bekker
IPC: A61K31/451 , A61K45/06 , A61P13/12 , A61K31/454
Abstract: Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
-
公开(公告)号：US11191756B2
公开(公告)日：2021-12-07
申请号：US16433487
申请日：2019-06-06
Applicant: CHEMOCENTRYX, INC.
Inventor： Jun Deng , Petrus Bekker , Jan Hillson
IPC: A61K31/445 , A61K9/00 , A61K31/675 , A61K31/573 , C07K16/28
Abstract: The present disclosure provides methods for treating ANCA-associate vasculitis in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of avacopan: or a pharmaceutically acceptable salt thereof, such that the level of plasma complement factor Bb, C3a, or C5a does not significantly change in the human upon treatment.
-
公开(公告)号：US20200179359A1
公开(公告)日：2020-06-11
申请号：US16791711
申请日：2020-02-14
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang MIAO , Israel CHARO , Tom SCHALL
IPC: A61K31/444 , A61K31/555 , A61K45/06 , A61K31/506 , A61K31/337 , A61K31/7068 , A61K31/282 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K38/19 , A61K31/53
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US11890276B2
公开(公告)日：2024-02-06
申请号：US17445640
申请日：2021-08-23
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC: A61K31/444 , A61K31/519 , A61K31/513 , A61K31/4745 , A61K31/282 , A61K31/7068 , A61K31/337 , A61K31/506 , A61K45/06 , A61K31/555 , A61K31/53 , A61K38/19 , A61K39/395
CPC classification number: A61K31/444 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/53 , A61K31/555 , A61K31/7068 , A61K38/19 , A61K39/395 , A61K45/06 , A61K31/519 , A61K2300/00 , A61K31/444 , A61K2300/00 , A61K31/555 , A61K2300/00 , A61K31/282 , A61K2300/00 , A61K31/513 , A61K2300/00 , A61K31/4745 , A61K2300/00 , A61K31/7068 , A61K2300/00 , A61K31/337 , A61K2300/00
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
Patent Agency Ranking
公开(公告)号：US11779576B2
公开(公告)日：2023-10-10
申请号：US17670604
申请日：2022-02-14
Applicant: CHEMOCENTRYX, INC.
Inventor： Petrus Bekker
IPC: A61K31/451 , A61K45/06 , A61P13/12 , A61K31/454
CPC classification number: A61K31/451 , A61K31/454 , A61K45/06 , A61P13/12
Abstract: Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
-
公开(公告)号：US20190167650A1
公开(公告)日：2019-06-06
申请号：US16266961
申请日：2019-02-04
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC: A61K31/444 , A61K31/506 , A61K31/337 , A61K31/7068 , A61K31/282 , A61K31/555 , A61K31/513 , A61K31/519 , A61K45/06 , A61K31/4745
CPC classification number: A61K31/444 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/506 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/7068 , A61K45/06 , A61K2300/00
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US11116756B2
公开(公告)日：2021-09-14
申请号：US16791711
申请日：2020-02-14
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC: A61K31/444 , A61K31/519 , A61K31/513 , A61K31/4745 , A61K31/282 , A61K31/7068 , A61K31/337 , A61K31/506 , A61K45/06 , A61K31/555 , A61K31/53 , A61K38/19 , A61K39/395
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US20190350911A1
公开(公告)日：2019-11-21
申请号：US16527933
申请日：2019-07-31
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC: A61K31/444 , A61K31/506 , A61K31/337 , A61K31/7068 , A61K31/282 , A61K31/555 , A61K31/513 , A61K31/519 , A61K45/06 , A61K31/4745
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
公开(公告)号：US10398685B2
公开(公告)日：2019-09-03
申请号：US16266961
申请日：2019-02-04
Applicant: ChemoCentryx, Inc.
Inventor： Petrus Bekker , Shichang Miao , Israel Charo , Tom Schall
IPC: A61K31/444 , A61K31/506 , A61K31/337 , A61K31/7068 , A61K31/4745 , A61K31/555 , A61K31/513 , A61K31/519 , A61K31/282 , A61K45/06
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.017 seconds)
